Prognostic implications of HER2NEU‐low in metastatic breast cancer

Documenti analoghi

• The efficiency and safety of low‐dose apatinib combined with oral vinorelbine in pretreated HER2‐negative metastatic breast cancer
  di: Jia‐Yi Huang, et al.
  Pubblicazione: (2024)
• Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France
  di: Thierry Petit, et al.
  Pubblicazione: (2024)
• Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
  di: Lan Chen, et al.
  Pubblicazione: (2024)
• Pathological and clinical outcomes following neoadjuvant dual HER2 therapy for early‐stage breast cancer: An Australian institutional real‐world experience
  di: Sathya Narayanan, et al.
  Pubblicazione: (2024)
• Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
  di: Xudong Zhang, et al.
  Pubblicazione: (2024)